31384-08-4 Usage
General Description
2,3-dihydropyrido[4,3-d]pyridazine-1,4-dione, also known as DPHPPD, is a chemical compound with a fused tricycle structure. It is a heterocyclic compound that contains two nitrogen atoms in its ring system. DPHPPD is a potent inhibitor of the enzyme soluble epoxide hydrolase, which is involved in the metabolism of fatty acids. 2,3-dihydropyrido[4,3-d]pyridazine-1,4-dione has potential therapeutic applications in the treatment of various diseases, including inflammation, pain, and cardiovascular disorders. Its unique structure and biological activity make DPHPPD an important molecule for medicinal chemistry research. Additionally, DPHPPD has been studied for its potential use in the development of new drugs for the treatment of cancer and other diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 31384-08-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,3,8 and 4 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 31384-08:
(7*3)+(6*1)+(5*3)+(4*8)+(3*4)+(2*0)+(1*8)=94
94 % 10 = 4
So 31384-08-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H5N3O2/c11-6-4-1-2-8-3-5(4)7(12)10-9-6/h1-3H,(H,9,11)(H,10,12)
31384-08-4Relevant articles and documents
Pyrido/pyridazocyclic compound and application thereof
-
Paragraph 0237-0241, (2019/12/25)
The invention discloses a pyrido/pyridazocyclic compound, a pharmaceutically acceptable salt and a solvent compound thereof. The invention further provides a preparation method of the compound, a composition with the compound and application of the compound for preparing medicines for treating diseases or disorders related to EED (embryonic ectoderm development) protein and/or PRC2 (polycomb repressive complex 2) protein composition action mechanisms.
HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS
-
Paragraph 00234, (2014/12/12)
This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.
